This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Infectious disease

Staphylococcus

Staphylococcus leukotoxin AB (lukAB); complement receptor 3 (CR3; CD11b); MAC-1 (CD11b-CD18)

Cell culture studies suggest inhibiting lukAB signaling could help treat Staphylococcus aureus infection. In cultured, neutrophil-like cells, immunoprecipitation experiments showed that lukAB directly bound the CD11b subunit of MAC-1. In these cells, small hairpin RNA knockdown of CD11b or pretreatment with an anti-CD11b antibody decreased S. aureus-mediated membrane damage compared with no knockdown or pretreatment. Next steps include developing additional tools to evaluate the contribution of lukAB to S. aureus pathogenicity during infections.

SciBX 6(27); doi:10.1038/scibx.2013.688
Published online July 18, 2013

Patent application filed; licensed to an undisclosed company

DuMont, A.L. et al. Proc. Natl. Acad. Sci. USA; published online June 10, 2013; doi:10.1073/pnas.1305121110
Contact: Victor J. Torres, New York University School of Medicine,
New York, N.Y.
e-mail:

victor.torres@nyumc.org